Clinical trials: System Sclerosis
Amyotrophic Lateral Sclerosis, ALS
MRI Biomarkers in ALS
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Motor Neuron Diseases
- Trial name
- NCT02405182
- Testing
- Magnetic Resonance Imaging
- Where
- 6 sites in Canada
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Multiple Sclerosis, Radiologically Isolated Syndrome
Diagnostic Value of eVOG
Eye movement is a complex neurological function controlled by many structures located in the central nervous system. The eyeball is mobile within the orbit and its movements are carried out using 6 muscles innervated by 3…
- Conditions
- Multiple Sclerosis, Radiologically Isolated Syndrome, White Matter Lesions
- Trial name
- DIVEyes (NCT05776511)
- Testing
- eVOG
- Where
- France
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Multiple Sclerosis
Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study
This prospective pilot study will assess the feasibility of remote participant monitoring using digital technology in participants with MS and healthy controls.
- Trial name
- NCT02952911
- Testing
- Smartphone and Smartwatch
- Where
- 2 sites in United States, Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Amyotrophic Lateral Sclerosis (ALS)
Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)
The overall goal of this research is to delay the respiratory decline of patients with Amyotrophic Lateral Sclerosis (ALS) thereby increasing their lifespan by conditioning the diaphragm with laparoscopically placed electrodes.
- Trial name
- NCT00420719
- Testing
- Intramuscular diaphragm electrodes
- Where
- 8 sites in United States, France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Synapse Biomedical
Multiple Sclerosis
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease.
- Trial name
- OUTCOMS (NCT04873492)
- Testing
- Biological sample collection
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Stroke, Ischemic, Stroke Hemorrhagic
Exploring Accessible Beauty for Individuals With Upper Extremity Deficits
The purpose of this study is to investigate the accessibility of beauty products for individuals with upper extremity disabilities.
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute
- Trial name
- NCT05945784
- Testing
- Use of Rare Beauty makeup products
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Casa Colina Hospital and Centers for Healthcare
Systemic Sclerosis
Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients
Today, the study of gut microbiota has taken a prominent place in several fields of medical research. Numerous experimental data in humans and animals suggest that an imbalance in the composition of the microbiota could…
- Trial name
- ScleroBiotique (NCT04132206)
- Testing
- stool sampling
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hôpital Européen Marseille
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Study of Electrical Impedance Myography (EIM) in ALS
This trial is studying Electrical Impedance Myography (EIM) for measuring muscle health. The trial is studying people with Amyotrophic Lateral Sclerosis (ALS), other neuromuscular diseases, and healthy volunteers to see if the…
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Charcot-Marie-Tooth Disease, Multiple Sclerosis
- Trial name
- NCT02011204
- Testing
- Electrical impedance myography (EIM)
- Where
- 6 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Skulpt, Inc.
Multiple Sclerosis, Breath Tests
The Relationship Between Mechanical Properties of Respiratory and Lower Extremity Muscles and Other Parameters in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease characterised by deterioration in the mechanics of the lower extremities and respiratory muscles and a decrease in respiratory function.
- Conditions
- Multiple Sclerosis, Breath Tests, MyotonPRO
- Trial name
- NCT07202780
- Where
- Turkey (Türkiye)
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Sanko University
Spinal Cord Injuries, Multiple Sclerosis
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
The UAB Institute for Arts In Medicine (AIM) is currently implementing an expressive emotional writing pilot project for adults with paralysis caused by neurological conditions such as traumatic head or spinal cord injury.
- Conditions
- Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT04721717
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Multiple Sclerosis, Multiple Sclerosis Lesion
Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study
The study proposal focuses on multiple sclerosis (MS), a chronic incurable disease of the central nervous system (CNS). The MS disease is characterised by recurrent transient disability progression, quantified by increase in the…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis Lesion, Multiple Sclerosis Brain Lesion
- Trial name
- AI ProMiS (NCT05426980)
- Where
- 4 sites in Slovenia
- Volunteers
- 654 people, healthy volunteers welcome
- Sponsor
- University of Ljubljana
Anxiety
Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis
It is a multicentric randomized and controlled study comparing a Scheme therapy program versus local practice in RRMS patients with anxiety.
- Trial name
- NCT04030819
- Testing
- schema therapy
- Where
- France
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Paris Nanterre University
Multiple Sclerosis
Telemonitoring and Connected Care Applied to Multiple Sclerose
The investigators designed a new care concept based on a multi-modal version of the MSmonitor program, the 'MSmonitor-Plus and Video Calling Care' (MPVC).
- Trial name
- MonSter (NCT05242731)
- Testing
- MSmonitor, a self-management/education program with e-health interventions, Video calling program "Better-close", Researchmanager program
- Where
- 4 sites in Netherlands
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Isala
Multiple Sclerosis, Relapsing-Remitting
Phase I BP Interferon (IFN) Beta-001
Phase I study aiming at: assessing the absolute bioavailability, pharmacokinetic profile, and dose proportionality of interferon beta-1a (HSA-free solution in pre-filled syringes) after i.v. and s.c.
- Trial name
- NCT02515695
- Testing
- Interferon beta-1a
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Multiple Sclerosis
The Relationship Between Fatigue and Physical Activity Level in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, progressive and unpredictable disease of the central nervous system. In MS, various loss of strength, balance and gait disturbances arise in the central nervous system due to sensory and/or…
- Trial name
- NCT03255460
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Gazi University
Systemic Sclerosis, Other Connective Tissue Disease
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis.
- Conditions
- Systemic Sclerosis, Other Connective Tissue Disease, Systemic Lupus Erythematosus, Dermatomyositis
- Trial name
- NETOSE (NCT06462768)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Primary Lateral Sclerosis, Hereditary Spastic Paraplegia
Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis
This study will use a magnetic resonance imaging technique called nuclear magnetic spectroscopy (H-MRS) to define the pathology and progression of primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral…
- Conditions
- Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Amyotrophic Lateral Sclerosis
- Trial name
- NCT00023075
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis, Relapsing-Remitting
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
GSK2018682 is a potent and selective agonist for the sphingosine-1- phosphate receptor subtype 1 (S1P1) with the potential to be an effective treatment for multiple sclerosis (MS).
- Trial name
- P1A114919 (NCT01466322)
- Testing
- GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Depressive Disorder, Major
Depression and Immune Function in Multiple Sclerosis (MS)
Depression is one of the most common symptoms of multiple sclerosis (MS) with a life-time prevalence of major depressive disorder (MDD) of up to 50%.
- Trial name
- DENIM (NCT02740296)
- Testing
- No intervention
- Where
- Germany
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany